Cargando…

412. Host Response Biomarkers Predict Clinical Failure in Patients with Staphylococcus aureus Bacteremia (SAB) Treated with Flucloxacillin (FLU) or Vancomycin (VAN)

BACKGROUND: Imbalance among innate mediators such as IL-1β, IL-10, and TNF-α portends poor outcomes of persistence and death in patients with SAB. Previous studies did not consider the role of antibiotic treatment in this important host–pathogen relationship. In this study of SAB, we determined cyto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aycock, Anna, Holmes, Natasha, Howden, Benjamin, Hayney, Mary, Sakoulas, George, Rose, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809857/ http://dx.doi.org/10.1093/ofid/ofz360.485

Ejemplares similares

637. Β-Lactam (BL) Antibiotics Promote an IL-1β Response in Patients with Staphylococcus aureus Bacteremia (SaB)
por: Volk, Cecilia, et al.
Publicado: (2018)

Complicated Staphylococcus aureus Bacteremia (SAB) Is Associated with Genetic Variation in GLS2
por: Fowler, Vance, et al.
Publicado: (2017)

182. Appropriateness of Treatment Duration for S. aureus Bacteremia (SAB)
por: Griebe, Kristin, et al.
Publicado: (2019)

Clinical Significance of Varying Degrees of Vancomycin Susceptilibity in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Schwaber, Mitchell J., et al.
Publicado: (2003)

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia
por: Schweizer, Marin L, et al.
Publicado: (2011)

764 Risk Factors for Failure of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Management of Staphylococcus aureus Bacteremia (SAB)
por: Veillette, John, et al.
Publicado: (2014)

1079. When Does a Trans-Esophageal Echocardiogram (TEE) Change Management of Staphylococcus aureus Bacteremia (SAB)?
por: Lam, John, et al.
Publicado: (2018)

1071. Impact of Standard vs. Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia (SAB) in Patients With Hematologic Malignancies
por: Cheung, Edna, et al.
Publicado: (2018)

1220. Impact of Mandatory Infectious Diseases Consultation on the Use of Core Measures and Mortality in Staphylococcus aureus Bacteremia (SAB) at an Academic Medical Center
por: Gancher, Elizabeth, et al.
Publicado: (2018)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Staphylococcus aureus Endovascular Infections?
por: Rose, Warren, et al.
Publicado: (2022)

High Vancomycin MIC and Complicated Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aguado, Jose Maria, et al.
Publicado: (2011)

Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy
por: Dhand, Abhay, et al.
Publicado: (2012)

The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia
por: Honda, Hitoshi, et al.
Publicado: (2011)

Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial
por: Thorlacius-Ussing, Louise, et al.
Publicado: (2019)

136. Factors Associated with Reduced Vancomycin Susceptibility in Pediatric Staphylococcus aureus Bacteremia
por: Ericson, Jessica E, et al.
Publicado: (2019)

Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations
por: Mills, Alexandra G., et al.
Publicado: (2023)

Sab
por: Gómez de Avellaneda y Arteaga, Gertrudis, 1814-1873
Publicado: (1976)

Proton-pump inhibitors do not influence clinical outcomes in patients with Staphylococcus aureus bacteremia
por: Caffrey, Aisling R., et al.
Publicado: (2019)

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.
por: Rotun, S S, et al.
Publicado: (1999)

Effectiveness of Daptomycin in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Vancomycin
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2017)

889. Impact of an Infectious Disease Telehealth (IDt) Service on S. aureus Bacteremia (SAB) Outcomes in 15 Small Community Hospitals
por: Gabrellas, Alithea D, et al.
Publicado: (2019)

Sab : novela
por: Gómez de Avellaneda y Arteaga, Gertrudis, 1814-1873
Publicado: (1970)

Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus
por: Machado, Henrique, et al.
Publicado: (2021)

Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis
por: Save, Jonathan, et al.
Publicado: (2022)

The Role of the Staphylococcal VraTSR Regulatory System on Vancomycin Resistance and vanA Operon Expression in Vancomycin-Resistant Staphylococcus aureus
por: Qureshi, Nadia K., et al.
Publicado: (2014)

Sab : novela original
por: Gómez de Avellaneda y Arteaga, Gertrudis, 1814-1873
Publicado: (1963)

Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia
por: Seah, Jonathan, et al.
Publicado: (2013)

1062. Daptomycin/Ceftaroline in Combination vs. Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Fox, Matthew, et al.
Publicado: (2018)

Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus
por: Komoto, Atsushi, et al.
Publicado: (2018)

187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021)

1033. Unexpected Allies: Vancomycin and Cefazolin Combination Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Caniff, Kaylee E, et al.
Publicado: (2023)

188. Plan PDD (patient directed discharge): Oral contingency plans for people who inject drugs (PWID) with Staphylococcus aureus bacteremia (SAB) who leave the hospital prematurely
por: Duffield, Olivia, et al.
Publicado: (2023)

Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia
por: Sakoulas, George, et al.
Publicado: (2016)

Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Trinh, Trang D, et al.
Publicado: (2017)

Molecular Confirmation of Vancomycin-Resistant Staphylococcus aureus with vanA Gene from a Hospital in Kathmandu
por: Maharjan, Meera, et al.
Publicado: (2021)

Genotypically Confirmed Vancomycin-Resistant Staphylococcus aureus With vanB Gene Among Clinical Isolates in Kathmandu
por: Nepal, Niranjan, et al.
Publicado: (2023)

264. Anti-platelet Therapy Significantly Reduces Inpatient Mortality in Patients with Staphylococcus aureus Bacteremia
por: Caffrey, Aisling, et al.
Publicado: (2020)

Vancomycin Resistance in Staphylococcus aureus 
por: McGuinness, Will A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_odt3jklrdvs1lnfhhmcfu6rsb3